|
|
|
@ -24,10 +24,10 @@ Attempt to build a "cannonical" probabalistic model of the clinical trials proce
|
|
|
|
- Documentation of code exists, and is useful.
|
|
|
|
- Documentation of code exists, and is useful.
|
|
|
|
|
|
|
|
|
|
|
|
# Models
|
|
|
|
# Models
|
|
|
|
The general benefit I can provide is to:
|
|
|
|
A couple of general principles.
|
|
|
|
|
|
|
|
|
|
|
|
- Describe the model in terms of conditional probability distributions (not expectations).
|
|
|
|
- Describe the model in terms of conditional probability distributions (not expectations).
|
|
|
|
- Model based on information known at the beginning of the trial.
|
|
|
|
- Model based on information known at the beginning of the trial. (benefit of the [data] in use)
|
|
|
|
- This might allow me to escape [[EK]]'s markov modeling approach for phase transitions.
|
|
|
|
- This might allow me to escape [[EK]]'s markov modeling approach for phase transitions.
|
|
|
|
|
|
|
|
|
|
|
|
## Phase completion: Joint Probability Estimation (single paper?)
|
|
|
|
## Phase completion: Joint Probability Estimation (single paper?)
|
|
|
|
|
Will King
4 years ago